ethyl 2-chloro-4H-furo[3,2-b]pyrrole-5-carboxylate | 332099-28-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 英文名称: ethyl 2-chloro-4H-furo[3,2-b]pyrrole-5-carboxylate
• 英文别名: 2-Chloro-4H-furo[3,2-b]pyrrole-5-carboxylic acid ethyl ester
• CAS: 332099-28-2
• 化学式: C₉H₈ClNO₃
• 分子量: 213.62
• InChiKey: BSIIENSVDCHCBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-chloro-4H-furo[3,2-b]pyrrole-5-carboxylate 在 sodium hydroxide 作用下， 以97%的产率得到2-Chloro-4H-furo[3,2-b]pyrrole-5-carboxylic acid
  参考文献：
  名称：

  The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

  摘要：

  The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

  DOI：

  10.1016/j.bmcl.2008.04.020
• 作为产物：
  描述：

  4H-呋喃并[3,2-b]吡咯-5-羧酸乙酯 在 磺酰氯 作用下， 以 乙醚 为溶剂， 反应 4.17h， 生成 ethyl 2-chloro-4H-furo[3,2-b]pyrrole-5-carboxylate
  参考文献：
  名称：

  FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

  摘要：

  这项发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病，如神经精神病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构：其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员，前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员，其中X+是正离子，从无机正离子和有机正离子中选择的成员。

  公开号：

  US20080004327A1

文献信息

• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• Fused heterocyclic inhibitors of D-amino acid oxidase
  申请人：Heffernan L. R. Michele

  公开号：US20080058395A1

  公开（公告）日：2008-03-06

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .

  本发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明化合物的制药组合物。同时，还提供了治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构：其中Q是从O、S、CR1和N中选择的成员，X和Y是独立选择自CR2、O、S、N和NR3的成员。
• Fluoro-substituted inhibitors of D-amino acid oxidase
  申请人：Sepracor Inc.

  公开号：US07884124B2

  公开（公告）日：2011-02-08

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

  本发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括本发明化合物的制药组合物。本发明还提供了用于治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。本发明化合物具有以下一般结构： 其中A为NH或S。Q为选择自CR1和N的成员。X和Y是独立选择自O、S、CR2、N和NH的成员。R1、R2和R4是独立选择自H和F的成员，但至少选择自R1、R2和R4中的一个成员为F。R6为选择自O−X+和OH的成员，其中X+为正离子，其为选择自无机正离子和有机正离子的成员。
• Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
  申请人：Pfizer Products Inc.

  公开号：EP1391460A1

  公开（公告）日：2004-02-25

  This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

  本发明涉及式 I 的化合物 或立体异构体、其药学上可接受的盐或原药或原药的药学上可接受的盐。本发明还涉及包含式 I 化合物的药物组合物，以及治疗糖尿病、胰岛素抵抗、糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变、白内障、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化或组织缺血的方法。
• NLRP3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
  申请人：제일약품주식회사

  公开号：KR20240022938A

  公开（公告）日：2024-02-20

  본 발명은 NLRP3 저해제로서 화학식 1로 표시되는 화합물, 이의 입체 이성질체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 포함하는 약학적 조성물에 관한 것으로, 상기 화합물, 이의 입체 이성질체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 포함하는 약학적 조성물은 NLRP3 활성 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있다. [화학식 1]

  本发明涉及一种NLRP3抑制剂，具体为化学式1所表示的化合物、其立体异构体或其药学上可接受的盐以及含有该化合物及其立体异构体或其药学上可接受的盐作为有效成分的药用组合物。所述化合物、其立体异构体或其药学上可接受的盐以及含有这些成分的药用组合物可用于预防或治疗与NLRP3活性相关的疾病。 [化学式1]